Paraganglioma

Table of Contents

1. What a Paraganglioma Is
2. Location and Types
3. Genetic Syndromes and Hereditary Disease
4. Clinical Presentation
5. Biochemical Diagnosis
6. Imaging and Functional Localization
7. Treatment — Surgery and Local Control
8. Treatment — Metastatic Disease
9. Surveillance and Long-Term Follow-Up
10. Key Research Papers
11. Connections
12. Featured Videos

What a Paraganglioma Is

To understand a paraganglioma, it helps to know a little about where the body's "fight-or-flight" cells come from. During fetal development, a special population of cells called the neural crest migrates out of the developing spinal cord and scatters throughout the body. Some of these cells become the adrenal medulla — the gland that pumps adrenaline when you're startled. Others settle into tiny nodules called paraganglia that sit alongside sympathetic and parasympathetic nerve chains everywhere from the jaw to the bladder. Normally these cells do their quiet jobs and never cause trouble. In paraganglioma, one of those nodules grows into a tumor.

The word "paraganglioma" literally means "tumor next to a ganglion (nerve cluster)." The critical distinction from pheochromocytoma is purely anatomical: pheochromocytoma = adrenal medulla; paraganglioma = everywhere else. Because these tumors share the same cell type and the same molecular machinery, oncologists now group them together as PPGLs and apply many of the same diagnostic and treatment protocols.

Paragangliomas split into two broad functional categories based on their location along the nervous system:

• Sympathetic paragangliomas — arise from sympathetic chain ganglia in the abdomen, pelvis, and chest. Most of these tumors actively secrete catecholamines (adrenaline-like hormones) and produce classic symptoms: surging blood pressure, pounding heartbeat, drenching sweats.
• Parasympathetic paragangliomas (head and neck paragangliomas, HNPGLs) — arise from parasympathetic ganglia clustered around the carotid artery, jugular vein, middle ear, and vagus nerve. The great majority are non-secretory — they do not release hormones — and instead present as a painless neck lump, a whooshing sound in the ear, or a cranial nerve problem.

Benign versus malignant. The 2022 WHO Classification of Endocrine and Neuroendocrine Tumors made a landmark change: it eliminated the words "benign" and "malignant" for PPGLs. Instead, all paragangliomas are considered tumors with metastatic potential. Metastatic disease is defined not by how the tumor looks under the microscope but by the presence of tumor in sites where paraganglionic tissue does not normally exist — typically lymph nodes, liver, lungs, and bone. Some tumors look completely normal under the microscope and still metastasize years later, which is why lifelong surveillance is essential for every patient.

Back to Table of Contents

Location and Types

Where a paraganglioma grows largely determines how it behaves, what symptoms it causes, and how it is treated. Surgeons and endocrinologists divide them by anatomical region:

Head and Neck Paragangliomas (HNPGLs)

HNPGLs are the most commonly diagnosed paragangliomas overall — partly because they sit in a region where a lump or unusual sound quickly prompts medical attention. Most are non-secretory.

• Carotid body tumors — the most common HNPGL. The carotid body is a small cluster of cells at the fork where the common carotid artery divides into its internal and external branches (just below the jaw). A tumor here causes a slow-growing, painless, pulsatile mass in the neck that can feel rubbery and moves side to side but not up and down. On an angiogram (blood-vessel X-ray) the tumor splays the carotid arteries apart in what radiologists call the "lyre sign" — the vessels spread like the strings of a lyre around the mass.
• Jugulotympanic paragangliomas — arise near the jugular foramen (the skull-base hole where the jugular vein exits) or in the middle ear. The classic symptom is pulsatile tinnitus — a rhythmic whooshing or pulsing sound in the ear that beats in time with the heartbeat. Patients also develop conductive hearing loss (the tumor physically blocks the ear canal or ossicles), and larger tumors damage cranial nerves IX through XII, causing problems with swallowing, voice hoarseness, shoulder weakness, or tongue deviation.
• Vagal paragangliomas — arise along the vagus nerve (cranial nerve X) in the neck, often higher up than carotid body tumors. They may cause hoarseness or swallowing difficulty before they are large enough to feel as a mass.

Abdominal and Pelvic Paragangliomas

These are sympathetic paragangliomas and are almost always functionally active — they secrete catecholamines and cause hormonal symptoms.

• Organ of Zuckerkandl — a cluster of paraganglia near the aortic bifurcation (where the main artery splits into the two iliac arteries in the lower abdomen). This is the most common site for abdominal extra-adrenal paraganglioma and is typically hormone-secreting.
• Bladder paraganglioma — a textbook-classic presentation: the patient experiences a hypertensive crisis or even syncope (fainting) specifically triggered by urination. Why? The detrusor muscle of the bladder contracts during urination, squeezing catecholamines out of the embedded tumor directly into the bloodstream. Patients may also notice blood in the urine (hematuria). This is rare enough that many clinicians miss it for years.
• Retroperitoneal — along the sympathetic chain in the posterior abdomen; often large at presentation.

Thoracic Paragangliomas

Thoracic paragangliomas arise from sympathetic ganglia alongside the spine (paravertebral). Cardiac paragangliomas — arising from tissue around the heart — are exceptionally rare but can cause cardiac symptoms including arrhythmia and heart failure from catecholamine excess.

Back to Table of Contents

Genetic Syndromes and Hereditary Disease

One of the most important things to know about paragangliomas is that they are the most hereditary of all endocrine tumors. About 35–40% of people diagnosed with a paraganglioma carry an inherited mutation in one of more than a dozen genes — compared with roughly 25% for pheochromocytoma and far less for most other cancers. This is why current guidelines recommend germline genetic testing for every patient with a paraganglioma, regardless of family history or age.

SDH Mutations — The Most Important Genes

The succinate dehydrogenase (SDH) gene family encodes an enzyme that sits inside the mitochondria and helps cells generate energy. Mutations that disable SDH cause a buildup of succinate — a metabolite that mimics low-oxygen conditions and tells the cell to grow. SDH mutations are responsible for the majority of hereditary paragangliomas:

• SDHB — the single most important mutation to identify. SDHB-mutant tumors carry a 30–40% lifetime risk of metastatic disease — far higher than any other PPGL subtype. They tend to arise in the abdomen, pelvis, and thorax. Because of this, centers image people with an SDHB mutation more often and search more widely for spread. In a series of 29 patients with SDHB-related abdominal or thoracic paraganglioma, 28% already had metastases when first seen and 90% had no family history of the disease, so these tumors often look "sporadic." Their hormone pattern was norepinephrine plus dopamine in 46%, norepinephrine only in 41% and dopamine only in 3%, and 10% made no excess hormones at all (biochemically silent).
• SDHD — strongly associated with head and neck paragangliomas, often multifocal (more than one tumor). SDHD follows an unusual inheritance pattern called maternal imprinting: only the copy of the gene inherited from the father is "switched on" in the relevant tissues. This means a child who inherits a mutation from their mother will not develop the disease (the maternal copy is silenced), but a child who inherits it from their father has a 50% chance of developing it. Genetic counselors explain this pattern to families because it changes who in the family is at risk.
• SDHC — mainly head and neck paragangliomas; lower malignancy risk than SDHB.
• SDHA — associated with both head-neck and abdominal PGLs; emerging recognition of malignancy risk.

Other Hereditary Syndromes

• Von Hippel-Lindau (VHL) — a syndrome of tumors including renal cell carcinoma, cerebellar hemangioblastomas, retinal angiomas, and PPGLs. VHL mutations disable a protein that normally targets hypoxia-sensing machinery for destruction; without it, the cell behaves as if it's always starving for oxygen.
• Neurofibromatosis type 1 (NF1) — caused by mutations in the NF1 tumor suppressor gene; pheochromocytoma is more common than paraganglioma in NF1, but both occur.
• Multiple Endocrine Neoplasia type 2 (MEN2) — RET gene mutations cause MEN2A (pheochromocytoma + medullary thyroid cancer + parathyroid hyperplasia) and MEN2B; pheochromocytoma predominates over paraganglioma in this syndrome.
• TMEM127 and MAX — newer genes; TMEM127 mutations cause bilateral pheochromocytoma and some paragangliomas; MAX mutations similarly affect both.

Because the hereditary rate is so high, a diagnosis of paraganglioma usually leads to cascade genetic testing: siblings, parents, and children of a mutation carrier can be tested and, if positive, enter surveillance programs before they ever develop symptoms.

Back to Table of Contents

Clinical Presentation

How paraganglioma presents depends almost entirely on where it is and whether it secretes hormones.

Secretory (Sympathetic) Paragangliomas

These tumors flood the bloodstream with catecholamines — norepinephrine, epinephrine, and sometimes dopamine — and produce symptoms identical to a pheochromocytoma:

• Paroxysmal (episodic) hypertension — blood pressure can spike to 200/120 mmHg or higher during a "spell," then normalize. These episodes may be spontaneous or triggered by pressure on the abdomen, a full bladder, certain medications (especially anesthetics and opioids), or physical exertion.
• The classic triad: headache, diaphoresis, and palpitations — occurring together during a spell is highly suggestive. Each symptom alone is common; all three together are a standard reason for a biochemical workup.
• Sustained hypertension — especially in young patients or those with hypertension resistant to multiple medications.
• Micturition-triggered spells (bladder paraganglioma) — a distinctive clue that the tumor is in the bladder wall.
• Pallor rather than flushing — catecholamines cause blood vessels to constrict, making the skin pale during a spell (opposite of carcinoid, which causes flushing).
• Anxiety and a sense of doom — the sudden surge of adrenaline-like hormones mimics a panic attack so closely that many patients are initially misdiagnosed with anxiety disorders.

Non-Secretory (Parasympathetic / Head and Neck) Paragangliomas

The most important thing to remember: normal blood pressure and normal hormone levels do not rule out a paraganglioma. HNPGLs are usually silent biochemically. They present with local mass effects:

• Painless, pulsatile neck mass — slow-growing; may be present for years before diagnosis.
• Pulsatile tinnitus — the patient hears their own heartbeat as a whooshing or pulsing sound; this is the hallmark of jugulotympanic paraganglioma.
• Conductive hearing loss — the tumor physically obstructs the middle ear.
• Cranial nerve deficits — depending on which nerves the tumor compresses at the skull base:
  • CN IX (glossopharyngeal): difficulty swallowing
  • CN X (vagus): hoarse voice, aspiration
  • CN XI (accessory): shoulder weakness/drop
  • CN XII (hypoglossal): tongue deviation toward the affected side
• Horner syndrome — drooping eyelid (ptosis), small pupil (miosis), and reduced sweating on one side of the face, when the tumor impinges on sympathetic fibers running alongside the carotid artery.

Metastatic Disease

Metastases most commonly involve bone (causing pain or pathological fractures), lymph nodes (palpable enlargement), liver, and lungs. Bone metastases are a particular concern in SDHB mutation carriers; they are painful and can be debilitating. Bone lesions are lytic (they erode rather than create new bone) and may not cause symptoms until significant destruction has occurred.

Back to Table of Contents

Biochemical Diagnosis

Diagnosing a paraganglioma biochemically is more nuanced than diagnosing a pheochromocytoma, because the key analyte is different depending on tumor location.

Plasma Fractionated Metanephrines — First-Line Test

Plasma fractionated metanephrines (measuring metanephrine and normetanephrine separately) are the most sensitive blood test for PPGLs overall. Catecholamines are converted continuously inside tumor cells to their metabolites — metanephrines — even between episodes, so a single blood draw can catch the tumor. A value more than 3–4 times the upper limit of normal is highly specific for a PPGL.

3-Methoxytyramine (3-MT) — The Key Marker for Paraganglioma

This is the critical extra step for paragangliomas that is often not ordered routinely. Many extra-adrenal and SDHB-related paragangliomas secrete dopamine rather than (or in addition to) norepinephrine or epinephrine. Dopamine is metabolized to 3-methoxytyramine (3-MT), and an elevated plasma 3-MT is a red flag for extra-adrenal paraganglioma, particularly of the SDHB subtype. Without measuring 3-MT, these tumors can be biochemically invisible on a standard metanephrine panel. For this reason, specialist centers measure plasma 3-MT alongside standard metanephrines when a paraganglioma is suspected.

24-Hour Urine Catecholamines and Metanephrines

An alternative or complementary approach: collecting all urine over 24 hours and measuring catecholamines (dopamine, norepinephrine, epinephrine) and their metabolites. This test captures episodic secretion over a longer time window and is sometimes more practical in community settings than plasma testing.

Non-Secretory Tumors — Biochemistry Is Normal

If the suspected tumor is a head and neck paraganglioma (carotid body, jugulotympanic, vagal), laboratory workup is very often completely normal. Diagnosis rests on imaging rather than biochemistry. It is not appropriate to "rule out" an HNPGL based on a normal metanephrine result — the two tests are asking different questions.

Chromogranin A

Chromogranin A is a protein stored in secretory granules and released by neuroendocrine tumors. It is elevated in most PPGLs, including non-secretory ones, and is useful as a tumor marker for monitoring — tracking treatment response and surveillance for recurrence — rather than for initial diagnosis.

Germline Genetic Testing

Because 35–40% of paragangliomas are hereditary, the Endocrine Society guidelines recommend offering germline testing to every patient. A negative biochemical workup does not change this recommendation. Identifying the specific mutation (SDHB, SDHD, VHL, etc.) guides surveillance intensity, risk counseling for family members, and sometimes treatment choice.

Back to Table of Contents

Imaging and Functional Localization

Once biochemical testing raises suspicion for a paraganglioma, imaging is needed to find the tumor and assess for metastatic spread. The field has shifted dramatically in recent years, with a new class of positron emission tomography (PET) scans replacing older nuclear medicine tests.

Anatomical Imaging — Computed Tomography and Magnetic Resonance Imaging

Computed tomography (CT) scan of the abdomen/pelvis/chest is usually the first imaging step for suspected abdominal or thoracic paragangliomas. Magnetic resonance imaging (MRI) is preferred for head and neck paragangliomas (better soft-tissue contrast, no radiation) and for any tumor near the spine or skull base. On magnetic resonance imaging, paragangliomas have a characteristic "salt-and-pepper" appearance on T2-weighted sequences — a speckled pattern of bright and dark spots caused by the tumor's rich blood supply and flow voids from large feeding vessels.

[68Ga]-DOTATATE PET/Computed Tomography — Now the Gold Standard

Paragangliomas express high levels of somatostatin receptors on their surface. [68Ga]-DOTATATE PET/computed tomography uses a radioactive tracer that binds to these receptors, lighting up wherever tumor cells are present — even tiny metastatic deposits in lymph nodes or bone that computed tomography would miss. Multiple studies have shown it outperforms all other functional imaging for paragangliomas, particularly for:

• Head and neck paragangliomas
• SDHB-related tumors and metastatic disease staging
• Multifocal disease

DOTATATE PET is now the recommended whole-body staging study for most paragangliomas and has largely replaced older tests.

[123I]-MIBG Scintigraphy

MIBG is a molecule that mimics norepinephrine and is taken up by cells that handle catecholamines. It was the standard functional imaging for decades. MIBG is still useful for secretory adrenal pheochromocytomas, but it is less sensitive for paragangliomas — particularly non-secretory and SDHB-related tumors — compared with DOTATATE PET. MIBG scanning is still performed before I-131 MIBG therapy (see below) to confirm the tumor will take up the therapeutic dose.

[18F]-FDG PET/Computed Tomography

Standard cancer positron emission tomography scanning (FDG) is useful for SDHB-related metastatic paraganglioma, where tumors can become highly glycolytic (glucose-hungry) and light up brightly on FDG — sometimes more so than on DOTATATE. For non-SDHB tumors, FDG PET is less informative. Using both DOTATATE PET and FDG PET provides the most complete picture in known or suspected metastatic disease.

Back to Table of Contents

Treatment — Surgery and Local Control

For localized, resectable paragangliomas, surgery with curative intent remains the cornerstone of treatment. However, pre-operative preparation is essential for any secretory tumor, and head and neck tumors present unique challenges where radiation may be preferred.

Pre-Operative Alpha-Blockade — Non-Negotiable for Secretory Tumors

Operating on a catecholamine-secreting paraganglioma without hormonal preparation is dangerous. Tumor manipulation during surgery releases a massive catecholamine surge, causing life-threatening hypertensive crises, arrhythmias, and cardiovascular collapse. To prevent this:

1. Alpha-adrenergic blockade first — phenoxybenzamine (a long-acting, non-competitive alpha-blocker) is started 10–14 days before surgery at doses of 10–40 mg/day. Blood pressure targets are below 130/80 mmHg seated, with allowable orthostatic dips (this is expected and desired).
2. Beta-blockade only after alpha is established — adding a beta-blocker before adequate alpha blockade can cause paradoxical severe hypertension (the alpha receptors are still active but the vasodilating beta-2 receptors are blocked).
3. High-sodium diet and liberal fluid intake — catecholamines cause chronic volume depletion; patients need to expand their blood volume before surgery or they will experience severe hypotension when the tumor is removed and catecholamine levels suddenly drop.

Surgical Approaches

• Abdominal/pelvic paragangliomas — laparoscopic or open retroperitoneal resection depending on size and location. Partial adrenalectomy is used where possible (to preserve adrenal cortex function), but is less relevant for extra-adrenal tumors.
• Head and neck paragangliomas — carotid body tumor resection is the most common; cranial nerve injury is the major risk (rates of 20–40% in expert centers for larger tumors). Jugulotympanic and vagal PGLs at the skull base are technically demanding; many centers prefer primary radiation to surgery for these locations to avoid cranial nerve deficits.
• Bladder paraganglioma — transurethral resection (for small intravesical tumors) or partial/radical cystectomy, depending on size and depth. Pre-operative alpha-blockade is essential: bladder manipulation without blockade can trigger a hypertensive crisis on the operating table.

Radiation for Head and Neck Paragangliomas

Stereotactic radiosurgery and fractionated stereotactic radiotherapy achieve excellent local control rates (90–95% at 10 years) for HNPGLs, with lower cranial nerve complication rates than surgery in experienced radiation centers. Radiation does not eliminate the tumor — it stops it from growing — so imaging surveillance continues lifelong. Radiation is often the preferred primary treatment for jugulotympanic and skull-base PGLs, while surgery remains preferred for carotid body tumors where resection is more straightforward.

Back to Table of Contents

Treatment — Metastatic Disease

Metastatic paraganglioma — tumor spread to sites where paraganglionic tissue doesn't normally exist — is a chronic, manageable but not yet curable condition in most cases. Several systemic treatments exist, and the choice depends on which radiotracer the tumor takes up (MIBG vs DOTATATE) and the pace of disease.

High-Dose [131I]-MIBG Therapy

For tumors that are MIBG-avid on diagnostic scan, high-dose radioactive MIBG can be delivered as targeted radiation. The U.S. Food and Drug Administration (FDA) approved high-specific-activity iobenguane I-131 in 2018 for unresectable, locally advanced or metastatic pheochromocytoma and paraganglioma; a 2026 review reports that its production has since been discontinued and it is not commercially available, while conventional (low-specific-activity) I-131 MIBG is still used off-label. Treatment requires hospitalization in a radiation-shielded room. In the pivotal trial (68 treated patients), 25% had a lasting cut of at least half in their blood-pressure medicines (the main goal of the study), 92% of 64 evaluable patients had a partial response or stable disease, and median overall survival was 36.7 months; the 2026 review gives the tumor shrinkage (objective response) rate as about 22–23%. It can meaningfully reduce catecholamine burden and improve quality of life. MIBG therapy is less effective for SDHB-related paragangliomas, which are less likely to be MIBG-avid.

Peptide Receptor Radionuclide Therapy (PRRT) — [177Lu]-DOTATATE

For tumors that express somatostatin receptors (DOTATATE-avid), lutetium-177 DOTATATE delivers targeted radiotherapy. Originally approved for neuroendocrine tumors of the gut and pancreas, PRRT is increasingly used off-label for DOTATATE-avid paragangliomas with growing evidence of efficacy. A 2026 review reports disease-control rates of 80–100% across prospective and retrospective studies. In a prospective phase II trial at the U.S. National Institutes of Health (36 evaluable patients, four treatment cycles), 86% were free of progression at 6 months and median progression-free survival was 20 months; partial responses grew from 14% at the end of treatment to 28% on follow-up, sporadic tumors did better (median 24.3 months) than SDHx tumors (12.9 months), and 18% had severe catecholamine-release events. Further studies in genetically defined groups are under way. For SDHB-related metastatic PGL that is DOTATATE-positive, PRRT is emerging as a preferred systemic approach.

Chemotherapy — CVD Regimen

Combination chemotherapy with CVD (cyclophosphamide, vincristine, dacarbazine) has been used in malignant PPGLs for decades. A 2014 meta-analysis of 4 studies (50 patients) found tumor shrinkage (partial response) in 37%, complete response in 4% and stable disease in 14%, with a partial response in hormone excess in 40%; the authors note the reported effect may partly reflect the natural course of the disease. CVD is typically reserved for rapidly progressing disease, MIBG-negative/DOTATATE-negative tumors, or when other options are exhausted. It is the only chemotherapy regimen with meaningful published data in this disease.

Targeted Therapies

• Sunitinib — a multi-target tyrosine kinase inhibitor that blocks VEGF receptors (angiogenesis). In FIRSTMAPPP, the first randomized trial ever done in this disease (78 patients with progressive metastatic PPGL), 36% of patients on sunitinib were free of progression at 12 months versus 19% on placebo; the authors call sunitinib the medical option with the highest level of evidence for anti-tumor effect. The most frequent severe side effects were weakness (18%) and high blood pressure (13%).
• Cabozantinib — another tyrosine kinase inhibitor; the single-arm phase II Natalie trial reported a 25% response rate in progressive metastatic PPGL.
• Belzutifan — a pill that blocks HIF-2α, the "false low-oxygen" signal switched on by SDHx and VHL changes. In the LITESPARK-015 phase 2 trial in advanced or metastatic PPGL, it gave a disease-control rate of 85% and a response rate of 26%, with better blood-pressure control; its most common side effect is anemia (grade 1–3). A 2026 article describes it as the first oral and the second FDA-approved therapy for metastatic PPGL.
• Temozolomide ± bevacizumab — temozolomide (an oral alkylating chemotherapy related to dacarbazine) has shown activity in SDHB-mutant paragangliomas. In a French study of 15 patients with progressive metastatic PPGL (10 with SDHB mutations), 33% had a partial response and 47% stable disease, median progression-free survival was 13.3 months, and partial responses occurred only in SDHB carriers; the authors link this to silencing of the DNA-repair gene MGMT in SDHB-mutant tumors. That study tested temozolomide alone, not the bevacizumab combination. Data support this combination in selected patients.

Management of metastatic paraganglioma is best handled at centers with multi-disciplinary PPGL tumor boards, ideally in the context of a clinical trial. Disease can remain indolent for years or decades in some patients (especially SDHD-related HNPGLs), while SDHB-related abdominal PGL can be aggressive. Matching treatment intensity to disease tempo is as important as the choice of agent.

Back to Table of Contents

Surveillance and Long-Term Follow-Up

One of the most important concepts in paraganglioma management: there is no such thing as "cured." Even after what appears to be a complete surgical resection with negative margins and no detectable metastases, paragangliomas can recur — sometimes 10, 15, or even 20+ years later. Lifelong follow-up is the standard of care for every patient.

Biochemical Surveillance

Annual measurement of plasma fractionated metanephrines and 3-methoxytyramine (for secretory tumors) or chromogranin A (for non-secretory HNPGLs) can detect recurrence before it is visible on imaging. A rising level prompts re-imaging even if the last scan was normal.

Imaging Surveillance

Cross-sectional imaging (computed tomography or magnetic resonance imaging) of the primary tumor bed every 2–3 years is typical for low-risk patients. SDHB mutation carriers receive more frequent surveillance — some centers image annually — because of the higher risk of metastatic disease. [68Ga]-DOTATATE PET is used when recurrence or metastasis is suspected rather than as routine annual surveillance (due to radiation exposure and cost).

Mutation-Specific Surveillance Differences

• SDHB carriers — highest priority for intensive follow-up; annual imaging; low threshold for functional positron emission tomography scanning when any concern arises.
• SDHD carriers — multifocal disease is common; scan the entire neck and skull base, not just the primary tumor site; the maternal imprinting rule means testing matters most for children of male SDHD carriers; children of female SDHD carriers are not at risk for the disease themselves (though they can transmit the mutation to their own children if they inherited it).
• VHL and NF1 carriers — these syndromes have surveillance protocols for other tumor types (renal, retinal, central nervous system) that run in parallel.

Family Cascade Testing

When a mutation is identified, first-degree relatives (parents, siblings, children) are offered genetic counseling and testing. For SDHD specifically, children of an affected father each have a 50% chance of inheriting the mutation. For SDHB and SDHC, standard autosomal dominant inheritance applies. Relatives who test positive enter surveillance programs and can be diagnosed before they have symptoms — catching tumors when they are small and surgically manageable.

Quality of Life Considerations

Living with a condition that requires lifelong monitoring — and that carries a real possibility of recurrence decades after initial treatment — creates significant psychological burden. Anxiety, fear of recurrence, and the stress of cascade testing on family members are real concerns. Patient advocacy communities such as the Pheo Para Alliance (a pheochromocytoma and paraganglioma patient organization) offer support, education, and clinical trial information.

Back to Table of Contents

Key Research Papers

1. Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(6):1915–1942.
   The authoritative clinical guideline covering diagnosis, genetic testing, preoperative management, and long-term surveillance for all PPGLs. The foundational reference for clinicians and informed patients.
   — PubMed PMID: 24893135
2. Fishbein L, Leshchiner I, Walter V, et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell. 2017;31(2):181–193.
   The TCGA comprehensive molecular profiling study of 173 PPGLs, classifying them into four molecular groups (kinase signaling, pseudohypoxia, Wnt-altered driven by MAML3 and CSDE1, and cortical admixture), naming CSDE1 as a new driver gene and the MAML3 fusion gene as a correlate of metastasis, and establishing the genomic landscape of these tumors.
   — PubMed PMID: 28162975
3. Timmers HJ, Kozupa A, Eisenhofer G, et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2007;92(3):779–786.
   Landmark paper establishing the high malignancy risk of SDHB mutations in paraganglioma and the distinctive dopamine/3-MT biochemical phenotype of extra-adrenal SDHB-related tumors.
   — PubMed PMID: 17200167
4. Taïeb D, Hicks RJ, Hindié E, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46(10):2112–2137.
   Comprehensive joint guideline on functional imaging for PPGLs, establishing [68Ga]-DOTATATE PET/CT as the preferred modality for most paraganglioma indications.
   — PubMed PMID: 31254038
5. Crona J, Taïeb D, Pacak K. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Endocr Rev. 2017;38(6):489–515.
   Reviews the molecular biology underlying PPGL classification, the SDH-related pseudohypoxia cluster, and implications for targeted therapy development.
   — PubMed PMID: 28938417
6. Neumann HP, Bausch B, McWhinney SR, et al. Germ-Line Mutations in Nonsyndromic Pheochromocytoma. N Engl J Med. 2002;346(19):1459–1466.
   Demonstrated that a remarkably high proportion (24%) of apparently sporadic pheochromocytoma/paraganglioma patients carry germline mutations, establishing the rationale for universal genetic testing.
   — PubMed PMID: 12000816
7. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB Gene Are Associated with Extra-Adrenal and/or Malignant Phaeochromocytomas. Cancer Res. 2003;63(17):5615–5621.
   One of the defining papers establishing SDHB mutations as a specific marker for malignant potential and extra-adrenal location in PPGLs.
   — PubMed PMID: 14500403
8. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results. J Clin Endocrinol Metab. 2003;88(6):2656–2666.
   Established plasma metanephrines as the most sensitive and specific biochemical test for PPGL and provided criteria for interpreting borderline results.
   — PubMed PMID: 12788870
9. Pryma DA, Chin BB, Noto RB, et al. Efficacy and Safety of High-Specific-Activity [131I]MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med. 2019;60(5):623–630.
   Pivotal phase 2 trial supporting FDA approval of high-specific-activity I-131 MIBG for advanced PPGL; 25% (17 of 68) had a durable reduction of at least half in blood-pressure medicines (the primary endpoint), 92% (59 of 64) had a partial response or stable disease, median overall survival 36.7 months.
   — PubMed PMID: 30291194
10. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of [177Lu]-DOTATATE for Midgut Neuroendocrine Tumors (NETTER-1). N Engl J Med. 2017;376(2):125–135.
    The landmark trial establishing PRRT efficacy for somatostatin receptor-positive neuroendocrine tumors; provides the mechanistic and clinical basis for PRRT use in DOTATATE-avid paragangliomas.
    — PubMed PMID: 28076709
11. Niemeijer ND, Alblas G, van Hulsteijn LT, et al. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;81(5):642–651.
    Meta-analysis of CVD chemotherapy (4 studies, 50 patients): tumor-volume partial response 37%, complete response 4%, stable disease 14%; partial hormonal response 40%; the authors note the effect may partly reflect the natural course of the disease.
    — PubMed PMID: 25041164
12. Hadoux J, Favier J, Scoazec JY, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014;135(11):2711–2720.
    Retrospective study of 15 patients: 33% partial responses, all in SDHB carriers; median progression-free survival 13.3 months; links response to MGMT silencing in SDHB-mutant tumors.
    — PubMed PMID: 24752622
13. Baudin E, Goichot B, Berruti A, et al. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. Lancet. 2024;403(10431):1061–1070.
    First randomized trial in metastatic PPGL (78 patients): 12-month progression-free survival 36% with sunitinib vs 19% with placebo.
    — PubMed PMID: 38402886
14. Jimenez C, Waguespack SG, Kaplan J, Habra MA, Varghese J. Belzutifan, a hypoxia-inducible factor 2-alpha inhibitor, for patients with advanced pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2026; online ahead of print (dgag324).
    Summarizes LITESPARK-015: disease-control rate 85%, response rate 26%; anemia the most common side effect.
    — PubMed PMID: 42573142
15. Hernandez-Felix JH, Golagha M, Jha A, et al. Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2026;33(7):e260036.
    Review of functional imaging and radioligand therapy; reports that high-specific-activity I-131 MIBG is not commercially available and that 177Lu-DOTATATE gave disease-control rates of 80–100%.
    — PubMed PMID: 42454478

PubMed Topic Searches

1. PubMed: Paraganglioma genetic syndrome SDH mutation
2. PubMed: Paraganglioma DOTATATE PET imaging
3. PubMed: Head and neck paraganglioma carotid body treatment
4. PubMed: Metastatic paraganglioma MIBG PRRT therapy
5. PubMed: Paraganglioma surveillance recurrence long-term

Back to Table of Contents

Back to Table of Contents

Connections

• Endocrinology
• Pheochromocytoma
• Multiple Endocrine Neoplasia Type 2 (MEN2)
• Carcinoid Tumor
• Adrenal Incidentaloma
• Adrenal Insufficiency
• Cushing's Syndrome
• Von Hippel-Lindau Disease
• Catecholamines Lab Test
• Chromogranin A Lab Test

Back to Table of Contents

Featured Videos